Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02902510
Other study ID # Pro00041068
Secondary ID
Status Completed
Phase N/A
First received September 5, 2016
Last updated September 14, 2016
Start date April 2015
Est. completion date April 2016

Study information

Verified date September 2016
Source Clemson University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a single blind, randomized, wait-list controlled, phase II exploratory pilot study.


Description:

This is a single blind, randomized, wait-list controlled, phase II exploratory pilot study utilizing an after-trial embedded mixed methods approach that will examine the efficacy of therapeutic yoga as a rehabilitation strategy for individuals with PD to improve balance and reduce fear of falling (FoF). Potential participants will have a FoF in order to enter the study. An after-trial embedded mixed methods design will be employed in this study and will include the collection of qualitative data to assist in the overall interpretation of the more heavily weighted quantitative trial data. Adding qualitative methods will serve as a post-hoc analysis capturing participant perceptions of the relationships between the yoga intervention and various outcomes. More specifically, the qualitative data will aide in explaining the link between the various yoga techniques and mechanisms that participants attribute to improved balance, reduced FoF, and other bio-psychosocial outcomes and experiences. Qualitative data will be collected using focus group interviews with participants in the yoga group at the end of the class in week 8.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of Parkinson's Disease with a rating of 1.5-4 on the Modified Hoehn and Yahr Scale of Parkinson's Disease Progression

- Endorsement of FoF,44 able to stand and walk 10 meters with or without an assistive device

- >18 years old; able to speak English

- Score >4 out of 6 on the short Mini Mental Status Exam

- Able and willing to attend twice weekly sessions for 8 weeks

Exclusion Criteria:

- People with self-reported life expectancy <12 months

- Inability to attend sessions due to transportation issues

- Current involvement with other physical activity (including yoga), rehabilitation, or other intervention studies

- Inability or refusal to provide informed consent

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Therapeutic yoga for people with Parkinson's Disease
Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Clemson University

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Movement Disorders Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale at 8 weeks A performance based assessment of motor function. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Primary Change in Mini BESTest at 8 weeks clinical balance assessment tool that targets 4 balance control systems, including anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Primary Change in Functional Gait Assessment at 8 weeks assesses postural stability during 10 walking tasks baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Secondary Change in Freezing of Gait Questionnaire at 8 weeks frequency of freezing of gait and disturbances in gait. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Secondary Change in Parkinson's Fatigue Scale at 8 weeks measures level of fatigue and impact of fatigue on daily functioning. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Secondary Change in Activity Balance Confidence Scale at 8 weeks Examines perceived confidence in performing various ambulatory activities with falling. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Secondary Change in Activity Constraints Scale at 8 weeks Measures perceived constraints to activity participation. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
Secondary Change in Parkinson's Disease Questionnaire (PDQ-8) at 8 weeks Measures quality of life for individuals with PD. baseline, 8 weeks (post-intervention), and for individuals in the WLC at the end of the 8-week waiting period No
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A